Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

General and administrative (G&A) expenses for the fourth quarter of 2024 were $24.1 million, compared to $14.2 million for the fourth quarter of 2023. G&A expenses for the full year 2024 were $77.1 ...

The introduction of ATRA had prompted several study groups to explore the role of ATRA either as a single agent or in combination with chemotherapy. Although treatment with single-agent ATRA ...

However, these advances are not uniform across the world. In the case of patients with acute myeloid leukaemia (AML), an aggressive form of blood cancer, these advances only reach a miniscule ...

CHICAGO, ILLINOIS / ACCESS Newswire / February 17, 2025 / The American Society for Transplantation and Cellular Therapy ® (ASTCT ®) is pleased to announce David L. Porter, MD, as the Society's ...

For example, investigational agents undergoing development for use in AML include FLT3 inhibitors, polo-like kinase inhibitors, farnesyltransferase inhibitors, HSP90 inhibitors, Mdm2 inhibitors ...

allowing a reduced Phase 3 trial size for Annamycin with Cytarabine also known as AnnAraC in treating R/R AML patients. The global "MIRACLE" trial will span the US, Europe, and the Middle East.

Annamycin's approval in AML alone would bring the potential to ... in Part A of the trial to receive high dose cytarabine (HiDAC) combined with either placebo, 190 mg/m2 of Annamycin, or 230 ...